By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genomic Health, Inc. 

301 Penobscot Drive

Redwood City  California  94063  U.S.A.
Phone: 650-556-9300 Fax: 650-556-1132


SEARCH JOBS

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 80 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.


Key Statistics


Email:
Ownership: Public

Web Site: Genomic Health
Employees:
Symbol: GHDX
 




Segment
Biotechnology





Company News
Genomic Health (GHDX) Announces Second Quarter 2017 Financial Results And Reports Recent Business Progress 8/2/2017 12:25:26 PM
Genomic Health (GHDX) To Announce Second Quarter 2017 Financial Results And Host Conference Call On Tuesday, August 1, 2017 7/20/2017 10:56:11 AM
Genomic Health (GHDX) Release: Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role Of Genomic Testing In Treatment Of Early Breast Cancer 7/12/2017 6:53:09 AM
Genomic Health (GHDX): New Data Show Important Role Of Genomic Testing In Treatment Of Older Breast Cancer Patients 6/6/2017 1:39:59 PM
Genomic Health (GHDX) Presents Data Further Demonstrating Ability Of Oncotype DX Tests To Optimize Outcomes In Patients Across Cancer Types 6/2/2017 7:13:18 AM
3 Things Investors Should Know About Genomic Health (GHDX) Stock 5/31/2017 6:10:15 AM
Genomic Health (GHDX) Release: Prospective Oncotype DX Genomic Prostate Score Test Data Presented At American Urological Association And Published In Urology Establish Test's Ability To Increase Use And Persistence On Active Surveillance In Prostate Cancer Patients 5/15/2017 6:59:05 AM
Genomic Health (GHDX) Release: Oncotype DX Genomic Prostate Score (GPS) Test Predicts 10-Year Risk Of Prostate Cancer-Specific Death And Metastases In Patients With Early-Stage Disease 5/15/2017 6:49:10 AM
Genomic Health (GHDX) Announces First Quarter 2017 Financial Results And Reports Recent Business Progress 5/10/2017 11:08:29 AM
Genomic Health (GHDX) Announces Favorable Draft Local Coverage Determination (LCD) On Medicare Coverage For Use Of Oncotype DX Genomic Prostate Score In Patients With Favorable Intermediate-Risk Prostate Cancer. 5/5/2017 7:59:45 AM
12345678910...
//-->